sparfloxacin has been researched along with cefuroxime in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (44.44) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Appelbaum, PC; Jacobs, MR; Visalli, MA | 1 |
Berche, P; Gehanno, P | 1 |
Cars, O; Löwdin, E; Odenholt, I | 1 |
Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
Fadeyi, A; Olajide, TG; Segun-Busari, S | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
1 trial(s) available for sparfloxacin and cefuroxime
Article | Year |
---|---|
Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. Sinusitis Study Group.
Topics: Acute Disease; Adult; Anti-Infective Agents; Cefuroxime; Cephalosporins; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Prodrugs; Quinolones; Sinusitis | 1996 |
8 other study(ies) available for sparfloxacin and cefuroxime
Article | Year |
---|---|
Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
Topics: Anti-Infective Agents; Cefuroxime; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Penicillin Resistance; Quinolones; Streptococcus pneumoniae | 1996 |
Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase.
Topics: Anti-Bacterial Agents; Azithromycin; Cefuroxime; Drug Administration Schedule; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Kinetics; Microbial Sensitivity Tests; Penicillin G; Quinolones; Streptococcus pyogenes | 1997 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
Bacteriological agents of chronic discharging ears and their antibiotic sensitivity pattern in Ido - Ekiti, Nigeria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Cefuroxime; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacteriaceae; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infant; Klebsiella; Male; Microbial Sensitivity Tests; Middle Aged; Nigeria; Otitis Media, Suppurative; Prospective Studies; Proteus; Pseudomonas; Staphylococcus aureus; Young Adult | 2012 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |